2017-11-15T10:36:56-06:00 2016-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1700 BELLEVUE WA 98004 990 2016-01-01 472231080 ALTIUS INSTITUTE FOR BIOMEDICAL SCIENCES ALTI 2067130124 2211 ELLIOT AVENUE NO 200 SEATTLE WA 98121 JOHN STAMATOYANNOPOULOS PRESIDENT/SCIENTIFIC DIRECTOR 2067130124 2017-11-14 1 JANE M SEARING P00000565 4254544919 2017-11-14 65.158.230.194 2017-11-14 10:34:51 PS P D3602557FBBC398886185FEEA8787C976E007265 51295D927CDB9749BD82B536CCA3BCF5FDE173CC 2016 2021-01-29 14:40:06Z LORI TONNES-PRIDDY 2211 ELLIOT AVENUE NO 200 SEATTLE WA 98121 27959116 0 X WWW.ALTIUSINSTITUTE.ORG X 2014 DE TO RADICALLY ENABLE AND ADVANCE BIOMEDICAL DISCOVERY THROUGH THE DEVELOPMENT AND EXPLORATORY APPLICATION OF NEW TECHNOLOGIES AND APPROACHES FOR ILLUMINATING CELL AND TISSUE STATES AND FUNCTION. TO ACHIEVE THIS VISION, ALTIUS IS ESTABLISHING A WHOLLY NEW TYPE OF SCIENTIFIC AND TECHNOLOGICAL DISCOVERY ENVIRONMENT DESIGNED TO FOSTER LEAPS IN INNOVATION. ALTIUS WILL LEVERAGE ITS CUTTING-EDGE TECHNOLOGIES TO SPAN THE CHASM BETWEEN BASIC BIOLOGICAL DISCOVERIES RELATED TO THE FUNCTION OF CELLS AND TISSUES AND THE TRANSLATION OF THESE INSIGHTS INTO THE CLINICAL ARENA AND THE DEVELOPMENT OF NOVEL MEDICINES. 2 1 75 1 0 0 19355575 27887418 0 0 1187 1676 0 70022 19356762 27959116 0 5000 0 0 1875590 8739105 0 0 0 5882351 11527815 7757941 20271920 11598821 7687196 15607317 21682398 3853427 8902692 11753890 12779706 X THE MISSION OF THE ALTIUS INSTITUTE FOR BIOMEDICAL SCIENCES (ALTIUS) IS TO RADICALLY ENABLE AND ADVANCE BIOMEDICAL DISCOVERY THROUGH THE DEVELOPMENT AND EXPLORATORY APPLICATION OF NEW TECHNOLOGIES AND APPROACHES FOR ILLUMINATING CELL AND TISSUE STATES AND FUNCTION. TO ACHIEVE THIS VISION, ALTIUS IS ESTABLISHING A WHOLLY NEW TYPE OF SCIENTIFIC AND TECHNOLOGICAL DISCOVERY ENVIRONMENT DESIGNED TO FOSTER LEAPS IN INNOVATION. ALTIUS WILL LEVERAGE ITS CUTTING-EDGE TECHNOLOGIES TO SPAN THE CHASM BETWEEN BASIC BIOLOGICAL DISCOVERIES RELATED TO THE FUNCTION OF CELLS AND TISSUES AND THE TRANSLATION OF THESE INSIGHTS INTO THE CLINICAL ARENA AND THE DEVELOPMENT OF NOVEL MEDICINES. 0 0 17925195 5000 ALTIUS DIRECTLY CONDUCTS AN ACTIVE AND MULTIFACETED PROGRAM OF BIOTECHNOLOGY RESEARCH. WE CONDUCT A CONSIDERABLE MAJORITY OF RESEARCH PROGRAMS DIRECTLY IN OUR OWN RESEARCH LABORATORY FACILITY, LOCATED IN SEATTLE. THE MEDICAL RESEARCH ORGANIZATION PROGRAM IS INTENDED TO GENERATE, DEVELOP AND TRANSLATE TO CLINICAL USE REGULATORY GENOMIC AND OTHER TECHNOLOGIES THAT HAVE TRANSFORMATIVE POTENTIAL IN BASIC BIOLOGY, BIOMEDICINE AND PHARMACEUTICAL DEVELOPMENT AND VALIDATION. INITIAL EFFORTS OF OUR RESEARCH PROGRAM FOCUS ON DEVELOPING A RICHER UNDERSTANDING OF HUMAN CELL MODELS, TARGETS AND MECHANISMS, FOR THE PURPOSE OF DEVELOPING NEW THERAPIES FOR DISEASE. TO THIS END, THE ORGANIZATION WILL FOCUS DEVELOPMENT ON DRIVING THE SCALING AND TRANSLATIONAL VALIDATION OF EXISTING CUTTING EDGE RESEARCH PLATFORMS, INCLUDING REGULATORY GENOMIC ANALYSES AND GENOME ENGINEERING TECHNOLOGIES. REGULATORY GENOMIC ANALYSIS YIELDS A HIGH-CONTENT, QUANTITATIVE ASSESSMENT OF INDIVIDUAL REGULATORY ELEMENTS, WHICH PROVIDES HIGHLY SENSITIVE MARKERS OF CELLULAR RESPONSE TO DISEASE AND TO CURRENT AND PAST DRUG EXPOSURES. SUCH ASSESSMENTS INFORM WHAT TISSUE AND TARGET TO STUDY, HOW TO MODULATE A DRUG TARGET, ANTICIPATE OFF-TARGET EFFECTS, AND PROTOTYPE DRUG TREATMENT EFFECTS. 17925195 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 2 0 1 75 1 0 0 0 0 0 0 0 0 0 0 X 2 1 0 0 0 0 1 1 1 1 0 0 0 0 1 1 1 1 1 1 0 0 X LORI TONNES-PRIDDY 2062671091 2211 ELLIOT AVENUE SUITE 200 SEATTLE WA 98121 JOHN STAMATOYANNOPOULOS PRESIDENT/SCIENTIFIC DIREC 40.00 X X 765975 0 18000 LON CARDEN DIRECTOR 1.00 X 0 0 0 STEPHANIE SEILER CHIEF OPERATING OFFICER THRU 2/16 40.00 X 56425 0 128 LORI TONNES-PRIDDY GENERAL COUNSEL/DIRECTOR OF ADMIN 40.00 X 229976 0 46892 FYODOR URNOV ASSOCIATE DIRECTOR 40.00 X 335333 0 1205 JEFFREY VIERSTRA INVESTIGATOR 40.00 X 241578 0 29047 JOHN NYHUIS INVESTIGATOR 40.00 X 153021 0 14249 ERIC RYNES SCIENTIST 40.00 X 138492 0 11508 ALEX REYNOLDS SCIENTIST 40.00 X 138180 0 11821 2058980 0 132850 13 0 1 0 UNIVERSITY OF WASHINGTON 1410 NE CAMPUS PARKWAY SEATTLE WA 98195 TESTING SERVICES 935503 SHREERAM AKILESH 8734 DAYTON AVE N SEATTLE WA 98103 SCIENTIFIC CONSULTING 235729 MONTKAE ASSOCIATES LLC 1326 FIFTH AVE SUITE 427 SEATTLE WA 98101 CONSTRUCTION PROJECT MNGMT 105066 3 3451294 24436124 27887418 1676 1676 REIMBURSEMENTS 900099 70022 70022 70022 27959116 0 0 71698 X 5000 5000 1117396 1006297 111099 5664207 5087587 576620 1957502 1838086 119416 102758 70366 32392 166284 113866 52418 651324 446007 205317 186244 5280 180964 319933 117625 202308 339166 262785 76381 1453000 1215249 237751 629398 411799 217599 573039 533283 39756 102033 -5754 107787 2038282 1955283 82999 45926 8186 37740 RESEARCH & DEVELOPMENT 3156664 3156664 RESEARCH COLLABORATIONS 1615348 1615348 BUSINESS TAX & LICENSE 104483 60758 43725 43933 21480 22453 20271920 17925195 2346725 0 8896880 4051828 2087248 2088923 2484757 94680 198761 14776855 2086516 4520171 12690339 23725 8338 144065 15607317 21682398 3687997 3363990 46521 2660584 165430 2831597 3853427 8902692 X 11753890 12779706 11753890 12779706 15607317 21682398 X 7687196 -6661380 X 0 0 0 X BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON SEATTLE WA BRIGHAM AND WOMEN'S HOSPITAL BOSTON MA YALE SCHOOL OF MEDICINE NEW HAVEN CT UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE SEATTLE WA RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 6060222 539989 5520233 7815517 1526524 6288993 901116 20003 881113 12690339 DEFERRED RENT 132872 CAPITAL LEASE OBLIGATION 1387294 LEASE INCENTIVE OBLIGATION, NET 1311431 2831597 27959116 0 27959116 0 27959116 20271920 0 20271920 0 20271920 EUROPE (INCLUDING ICELAND & GREENLAND) 0 1 PROGRAM SERVICES TRAVEL FOR EDUCATION, NETWORKING, GRANT SEEKING AND FUNDRAISING 290000 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES MICROSCOPY SERVICES 11849 0 1 0 0 0 1 301849 0 301849 0 0 0 0 0 0 X 0 1 X X 0 0 0 0 0 0 0 0 0 JOHN STAMATOYANNOPOULOS PRESIDENT/SCIENTIFIC DIREC 750000 0 0 0 15975 0 18000 0 0 0 783975 0 0 0 LORI TONNES-PRIDDY GENERAL COUNSEL/DIRECTOR OF ADMIN 229976 0 0 0 0 0 18000 0 28892 0 276868 0 0 0 FYODOR URNOV ASSOCIATE DIRECTOR 335333 0 0 0 0 0 0 0 1205 0 336538 0 0 0 JEFFREY VIERSTRA INVESTIGATOR 241578 0 0 0 0 0 27000 0 2047 0 270625 0 0 0 JOHN NYHUIS INVESTIGATOR 153021 0 0 0 0 0 13493 0 756 0 167270 0 0 0 ALEX REYNOLDS SCIENTIST 138180 0 0 0 0 0 10813 0 1008 0 150001 0 0 0 PART I, LINE 1A JOHN STAMATOYANNOPOULOS AND LORI PRIDDY-TONNES PARTICIPATED IN FIRST CLASS TRAVEL. THIS WAS NOT TREATED AS TAXABLE INCOME TO THE INDIVIDUALS. PART I, LINE 1B DURING 2016 THE ORGANIZATION DID NOT HAVE A WRITTEN POLICY REGARDING THE PAYMENT OR REIMBURSEMENT OF FIRST CLASS TRAVEL. FORM 990, PART VI, SECTION A, LINE 6 THE ORGANIZATION HAS ONE CLASS OF MEMBERSHIP WHICH INCLUDES TWO MEMBERS, DR. JOHN STAMATOYANNOPOULOS (OR HIS DESIGNEE) AND GLAXOSMITHKLINE LLC. FORM 990, PART VI, SECTION A, LINE 7A THE MEMBERS OF THE ORGANIZATION ARE ENTITLED TO ELECT DIRECTORS OF THE BOARD AND REMOVE ONLY DIRECTORS WHICH THEY HAVE APPOINTED. FORM 990, PART VI, SECTION A, LINE 7B THE ELECTION AND REMOVAL OF DIRECTORS OF THE BOARD IS SUBJECT TO APPROVAL BY UNANIMOUS VOTE OF THE MEMBERS. FORM 990, PART VI, SECTION A, LINE 8B THE ORGANIZATION'S SECRETARY DOCUMENTS MEETINGS AND WRITTEN ACTIONS OF ITS GOVERNING BODY. THE ORGANIZATION DID NOT HAVE COMMITTEES IN 2016 DUE TO THE SMALL SIZE OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 11B THE PRESIDENT/SCIENTIFIC DIRECTOR WILL REVIEW THE FORM 990 PRIOR TO ITS SUBMISSION TO THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION'S CONFLICT OF INTEREST POLICY REQUIRES COVERED PERSONS, DEFINED AS ANY DIRECTOR, OFFICER, OR MEMBER OF A COMMITTEE OF THE BOARD OF DIRECTORS, TO COMPLETE AND SIGN AN ANNUAL CONFLICT OF INTEREST QUESTIONNAIRE. THE QUESTIONNAIRE REQUIRES DISCLOSURE OF ANY POTENTIAL OR ACTUAL CONFLICTS OF INTEREST AND IS SIGNED BY THE COVERED PERSON, AFFIRMING THAT THE INDIVIDUAL HAS RECEIVED A COPY OF, READ, UNDERSTANDS, AND WILL COMPLY WITH THE ORGANIZATION'S CONFLICT OF INTEREST POLICY. IF A POTENTIAL OR ACTUAL CONFLICT OF INTEREST ARISES, THE INDIVIDUAL MUST RECUSE HIMSELF OR HERSELF FROM VOTING ON THE MATTER AND MUST NOT BE PRESENT WHEN ANY SUCH VOTE IS TAKEN. THE BOARD OF DIRECTORS EVALUATES ALL DISCLOSURES REPORTED TO DETERMINE WHETHER AN ACTUAL CONFLICT OF INTEREST EXISTS. POTENTIAL OR ACTUAL CONFLICTS OF INTEREST ARE DOCUMENTED IN THE MINUTES OF MEETINGS OF THE BOARD OF DIRECTORS AND COMMITTEE'S OF THE BOARD. FORM 990, PART VI, SECTION B, LINE 15A A COMPENSATION STUDY WAS CONDUCTED BY AN OUTSIDE CONSULTANT IN 2015 TO DETERMINE THE COMPENSATION FOR THE PRESIDENT AND CONSTRUCT A WRITTEN EMPLOYMENT CONTRACT. COMPENSATION OF SIMILAR ORGANIZATIONS WAS CONSIDERED AND THE WRITTEN CONTRACT WAS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS. THE CONTRACT IS EFFECTIVE THROUGH JUNE, 2017. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. PART IX, FUNCTIONAL EXPENSE ALLOCATION ALL EXPENSES ASSOCIATED WITH OBTAINING GRANTS ARE INCLUDED IN PROGRAM AND GENERAL AND ADMINISTRATIVE EXPENSES AS ALLOWED UNDER THE INDIRECT COST RECOVERY PROVISIONS OF THE GRANT AGREEMENT. FORM 990, PART XI, LINE 9: TO RECORD PRIOR YEAR FUNDING ON AN EXPENSE REIMBURSEMENT BASIS -7,056,230. TO BOOK TENANT IMPROVMENTS AND OTHER FIXED ASSETS IN ACCORDANCE WITH GAAP 121,061. TO RECOGNIZE EXPENSES FOR A 2015 CONFERENCE PAID IN 2016 273,789.